Trial Outcomes & Findings for Spectroscopic Imaging at 4T: A Drug Challenge Study (NCT NCT01577706)
NCT ID: NCT01577706
Last Updated: 2017-04-04
Results Overview
The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge. GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100\*(later timepoint - earlier timepoint) / earlier timepoint
Recruitment status
TERMINATED
Study phase
NA
Target enrollment
7 participants
Primary outcome timeframe
from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)
Results posted on
2017-04-04
Participant Flow
Participant milestones
| Measure |
Dextroamphetamine, Alprazolam, Placebo Sequence
Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Alprazolam: Alprazolam, gel-capsule, 1mg, single-dose, 1-day Dextroamphetamine: Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day
Placebo: single-dose, 1-day
|
Alprazolam, Dextroamphetamine, Placebo Sequence
Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Alprazolam: Alprazolam, gel-capsule, 1mg, single-dose, 1-day Dextroamphetamine: Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day
Placebo: single-dose, 1-day
|
Placebo, Dextroamphetamine, Alprazolam Sequence
Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Alprazolam: Alprazolam, gel-capsule, 1mg, single-dose, 1-day Dextroamphetamine: Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day
Placebo: single-dose, 1-day
|
|---|---|---|---|
|
First Intervention (1 Day)
STARTED
|
3
|
1
|
3
|
|
First Intervention (1 Day)
COMPLETED
|
3
|
1
|
3
|
|
First Intervention (1 Day)
NOT COMPLETED
|
0
|
0
|
0
|
|
Washout (at Least 1 Week)
STARTED
|
3
|
1
|
3
|
|
Washout (at Least 1 Week)
COMPLETED
|
3
|
1
|
3
|
|
Washout (at Least 1 Week)
NOT COMPLETED
|
0
|
0
|
0
|
|
Second Intervention (1 Day)
STARTED
|
3
|
1
|
3
|
|
Second Intervention (1 Day)
COMPLETED
|
3
|
1
|
3
|
|
Second Intervention (1 Day)
NOT COMPLETED
|
0
|
0
|
0
|
|
Third Intervention (1 Day)
STARTED
|
3
|
1
|
3
|
|
Third Intervention (1 Day)
COMPLETED
|
3
|
1
|
3
|
|
Third Intervention (1 Day)
NOT COMPLETED
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Spectroscopic Imaging at 4T: A Drug Challenge Study
Baseline characteristics by cohort
| Measure |
All Study Participants
n=7 Participants
Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Alprazolam: Alprazolam, gel-capsule, 1mg, single-dose, 1-day
Dextroamphetamine: Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day
|
|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
7 Participants
n=5 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=5 Participants
|
|
Age, Continuous
|
28.9 years
STANDARD_DEVIATION 7.6 • n=5 Participants
|
|
Sex: Female, Male
Female
|
0 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
7 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
7 participants
n=5 Participants
|
PRIMARY outcome
Timeframe: from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge. GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100\*(later timepoint - earlier timepoint) / earlier timepoint
Outcome measures
| Measure |
Placebo
n=7 Participants
Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Placebo: single-dose, 1-day
|
Alprazolam
n=7 Participants
Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Alprazolam: Alprazolam, gel-capsule, 1mg, single-dose, 1-day
|
Dextroamphetamine
n=7 Participants
Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Dextroamphetamine: Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day
|
|---|---|---|---|
|
Left Thalamus: Percent Change in GABA Levels After an Acute Drug Challenge
t1 to t2: 45min-64min
|
-6.80 percent change
Interval -21.48 to 16.18
|
23.57 percent change
Interval -1.97 to 64.94
|
-12.51 percent change
Interval -21.04 to 21.22
|
|
Left Thalamus: Percent Change in GABA Levels After an Acute Drug Challenge
t1 to t3: 45min-83min
|
-2.63 percent change
Interval -7.82 to 16.87
|
39.29 percent change
Interval 29.17 to 50.69
|
8.26 percent change
Interval -8.12 to 46.09
|
|
Left Thalamus: Percent Change in GABA Levels After an Acute Drug Challenge
t1 to t4: 45min-102min
|
10.01 percent change
Interval -25.15 to 25.52
|
23.30 percent change
Interval 17.75 to 58.61
|
13.63 percent change
Interval -1.96 to 44.44
|
|
Left Thalamus: Percent Change in GABA Levels After an Acute Drug Challenge
t2 to t3: 64min-83min
|
4.47 percent change
Interval -16.73 to 52.66
|
12.72 percent change
Interval 1.46 to 37.76
|
17.75 percent change
Interval 5.02 to 30.2
|
|
Left Thalamus: Percent Change in GABA Levels After an Acute Drug Challenge
t3 to t4: 83min-102min
|
-6.32 percent change
Interval -20.28 to 32.66
|
-2.10 percent change
Interval -10.9 to 9.2
|
5.45 percent change
Interval -22.42 to 25.76
|
|
Left Thalamus: Percent Change in GABA Levels After an Acute Drug Challenge
t2 to t4: 64min-102min
|
15.44 percent change
Interval -16.72 to 47.92
|
10.79 percent change
Interval -4.71 to 44.32
|
24.16 percent change
Interval -0.26 to 38.62
|
PRIMARY outcome
Timeframe: from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge. GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100\*(later timepoint - earlier timepoint) / earlier timepoint
Outcome measures
| Measure |
Placebo
n=7 Participants
Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Placebo: single-dose, 1-day
|
Alprazolam
n=7 Participants
Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Alprazolam: Alprazolam, gel-capsule, 1mg, single-dose, 1-day
|
Dextroamphetamine
n=7 Participants
Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Dextroamphetamine: Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day
|
|---|---|---|---|
|
Left Basal-Ganglia: Percent Change in GABA Levels After an Acute Drug Challenge
t1 to t2: 45min-64min
|
-2.91 percent change
Interval -32.57 to 40.7
|
43.17 percent change
Interval 12.28 to 47.33
|
5.28 percent change
Interval -6.26 to 39.08
|
|
Left Basal-Ganglia: Percent Change in GABA Levels After an Acute Drug Challenge
t1 to t3: 45min-83min
|
2.11 percent change
Interval -12.57 to 24.86
|
43.09 percent change
Interval 0.95 to 121.66
|
17.06 percent change
Interval -8.04 to 58.61
|
|
Left Basal-Ganglia: Percent Change in GABA Levels After an Acute Drug Challenge
t1 to t4: 45min-102min
|
15.59 percent change
Interval -24.01 to 47.89
|
44.26 percent change
Interval 26.85 to 57.43
|
14.68 percent change
Interval -24.68 to 80.77
|
|
Left Basal-Ganglia: Percent Change in GABA Levels After an Acute Drug Challenge
t2 to t3: 64min-83min
|
-0.58 percent change
Interval -31.51 to 49.01
|
6.57 percent change
Interval -7.83 to 35.21
|
13.40 percent change
Interval -1.9 to 14.04
|
|
Left Basal-Ganglia: Percent Change in GABA Levels After an Acute Drug Challenge
t3 to t4: 83min-102min
|
2.66 percent change
Interval -23.72 to 99.09
|
3.53 percent change
Interval -30.3 to 42.9
|
20.19 percent change
Interval -32.47 to 47.63
|
|
Left Basal-Ganglia: Percent Change in GABA Levels After an Acute Drug Challenge
t2 to t4: 64min-102min
|
5.10 percent change
Interval -21.73 to 45.14
|
-4.57 percent change
Interval -25.72 to 28.48
|
22.34 percent change
Interval 3.56 to 32.7
|
PRIMARY outcome
Timeframe: from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)Population: One participant is missing GABA level at t4 while on Placebo, and one participant is missing GABA level at t2 while on Alprazolam.
The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge. GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100\*(later timepoint - earlier timepoint) / earlier timepoint
Outcome measures
| Measure |
Placebo
n=7 Participants
Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Placebo: single-dose, 1-day
|
Alprazolam
n=7 Participants
Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Alprazolam: Alprazolam, gel-capsule, 1mg, single-dose, 1-day
|
Dextroamphetamine
n=7 Participants
Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Dextroamphetamine: Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day
|
|---|---|---|---|
|
Left Temporal: Percent Change in GABA Levels After an Acute Drug Challenge
t1 to t2: 45min-64min
|
-10.24 percent change
Interval -30.56 to 97.99
|
4.38 percent change
Interval -22.54 to 60.19
|
6.36 percent change
Interval -9.12 to 58.23
|
|
Left Temporal: Percent Change in GABA Levels After an Acute Drug Challenge
t1 to t3: 45min-83min
|
-13.82 percent change
Interval -61.55 to -10.61
|
13.44 percent change
Interval -18.74 to 56.65
|
1.34 percent change
Interval -12.22 to 15.03
|
|
Left Temporal: Percent Change in GABA Levels After an Acute Drug Challenge
t1 to t4: 45min-102min
|
-8.77 percent change
Interval -17.82 to 7.78
|
58.49 percent change
Interval -56.01 to 98.58
|
18.24 percent change
Interval -15.13 to 31.52
|
|
Left Temporal: Percent Change in GABA Levels After an Acute Drug Challenge
t2 to t3: 64min-83min
|
-10.55 percent change
Interval -34.46 to 24.1
|
14.55 percent change
Interval -2.21 to 48.14
|
-6.70 percent change
Interval -27.3 to 15.62
|
|
Left Temporal: Percent Change in GABA Levels After an Acute Drug Challenge
t3 to t4: 83min-102min
|
3.83 percent change
Interval -4.64 to 55.05
|
32.81 percent change
Interval -45.86 to 44.54
|
7.53 percent change
Interval -20.13 to 29.78
|
|
Left Temporal: Percent Change in GABA Levels After an Acute Drug Challenge
t2 to t4: 64min-102min
|
-2.03 percent change
Interval -40.16 to 1.63
|
19.68 percent change
Interval -43.21 to 54.55
|
-20.20 percent change
Interval -26.64 to 15.38
|
PRIMARY outcome
Timeframe: from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge. GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100\*(later timepoint - earlier timepoint) / earlier timepoint
Outcome measures
| Measure |
Placebo
n=7 Participants
Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Placebo: single-dose, 1-day
|
Alprazolam
n=7 Participants
Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Alprazolam: Alprazolam, gel-capsule, 1mg, single-dose, 1-day
|
Dextroamphetamine
n=7 Participants
Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Dextroamphetamine: Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day
|
|---|---|---|---|
|
Parieto-Occipital: Percent Change in GABA Levels After an Acute Drug Challenge
t1 to t2: 45min-64min
|
6.09 percent change
Interval -14.53 to 23.67
|
-0.51 percent change
Interval -26.89 to 22.96
|
39.69 percent change
Interval -12.79 to 47.24
|
|
Parieto-Occipital: Percent Change in GABA Levels After an Acute Drug Challenge
t1 to t3: 45min-83min
|
-1.60 percent change
Interval -13.79 to 21.08
|
1.90 percent change
Interval -4.5 to 13.63
|
-10.29 percent change
Interval -21.14 to 21.33
|
|
Parieto-Occipital: Percent Change in GABA Levels After an Acute Drug Challenge
t1 to t4: 45min-102min
|
24.54 percent change
Interval -1.31 to 59.63
|
21.95 percent change
Interval 5.9 to 41.0
|
22.35 percent change
Interval 1.0 to 56.99
|
|
Parieto-Occipital: Percent Change in GABA Levels After an Acute Drug Challenge
t2 to t3: 64min-83min
|
2.15 percent change
Interval -20.41 to 30.46
|
4.64 percent change
Interval -7.82 to 37.25
|
-17.33 percent change
Interval -41.0 to 2.01
|
|
Parieto-Occipital: Percent Change in GABA Levels After an Acute Drug Challenge
t3 to t4: 83min-102min
|
21.76 percent change
Interval 15.07 to 33.23
|
10.78 percent change
Interval -8.66 to 33.39
|
36.38 percent change
Interval 19.58 to 65.32
|
|
Parieto-Occipital: Percent Change in GABA Levels After an Acute Drug Challenge
t2 to t4: 64min-102min
|
33.46 percent change
Interval 3.73 to 50.47
|
18.83 percent change
Interval 3.59 to 41.72
|
7.97 percent change
Interval -19.53 to 26.83
|
PRIMARY outcome
Timeframe: from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)Population: One participant ismissing GABA level at t4 while on Dextroamphetamine
The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge. GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100\*(later timepoint - earlier timepoint) / earlier timepoint
Outcome measures
| Measure |
Placebo
n=7 Participants
Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Placebo: single-dose, 1-day
|
Alprazolam
n=7 Participants
Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Alprazolam: Alprazolam, gel-capsule, 1mg, single-dose, 1-day
|
Dextroamphetamine
n=7 Participants
Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Dextroamphetamine: Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day
|
|---|---|---|---|
|
Right Thalamus: Percent Change in GABA Levels After an Acute Drug Challenge
t1 to t2: 45min-64min
|
6.55 percent change
Interval -6.15 to 44.75
|
2.72 percent change
Interval -9.2 to 8.24
|
-3.61 percent change
Interval -28.4 to 20.53
|
|
Right Thalamus: Percent Change in GABA Levels After an Acute Drug Challenge
t1 to t3: 45min-83min
|
7.26 percent change
Interval 3.35 to 19.28
|
19.20 percent change
Interval 0.03 to 26.12
|
14.63 percent change
Interval -15.89 to 33.19
|
|
Right Thalamus: Percent Change in GABA Levels After an Acute Drug Challenge
t1 to t4: 45min-102min
|
8.39 percent change
Interval -14.79 to 56.45
|
4.54 percent change
Interval -9.9 to 25.8
|
30.23 percent change
Interval 20.15 to 43.23
|
|
Right Thalamus: Percent Change in GABA Levels After an Acute Drug Challenge
t2 to t3: 64min-83min
|
-7.13 percent change
Interval -16.64 to 10.54
|
16.51 percent change
Interval 7.97 to 35.51
|
14.95 percent change
Interval -13.8 to 33.15
|
|
Right Thalamus: Percent Change in GABA Levels After an Acute Drug Challenge
t3 to t4: 83min-102min
|
2.87 percent change
Interval -17.56 to 31.88
|
-1.78 percent change
Interval -24.21 to 1.69
|
1.60 percent change
Interval -15.84 to 4.82
|
|
Right Thalamus: Percent Change in GABA Levels After an Acute Drug Challenge
t2 to t4: 64min-102min
|
12.69 percent change
Interval -9.21 to 13.71
|
12.12 percent change
Interval -11.69 to 38.55
|
15.51 percent change
Interval 10.05 to 24.66
|
PRIMARY outcome
Timeframe: from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)Population: One participant is missing GABA level at t4 while on Dextroamphetamine.
The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge. GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100\*(later timepoint - earlier timepoint) / earlier timepoint
Outcome measures
| Measure |
Placebo
n=7 Participants
Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Placebo: single-dose, 1-day
|
Alprazolam
n=7 Participants
Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Alprazolam: Alprazolam, gel-capsule, 1mg, single-dose, 1-day
|
Dextroamphetamine
n=7 Participants
Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Dextroamphetamine: Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day
|
|---|---|---|---|
|
Right Basal-Ganglia: Percent Change in GABA Levels After an Acute Drug Challenge
t1 to t2: 45min-64min
|
18.63 percent change
Interval -13.56 to 32.9
|
-9.44 percent change
Interval -33.69 to -1.73
|
38.78 percent change
Interval -20.68 to 69.65
|
|
Right Basal-Ganglia: Percent Change in GABA Levels After an Acute Drug Challenge
t1 to t3: 45min-83min
|
-3.97 percent change
Interval -27.05 to 21.12
|
3.03 percent change
Interval -19.95 to 34.72
|
67.41 percent change
Interval 4.27 to 106.38
|
|
Right Basal-Ganglia: Percent Change in GABA Levels After an Acute Drug Challenge
t1 to t4: 45min-102min
|
-1.53 percent change
Interval -18.69 to 146.9
|
33.58 percent change
Interval -7.07 to 35.39
|
37.92 percent change
Interval -34.2 to 69.05
|
|
Right Basal-Ganglia: Percent Change in GABA Levels After an Acute Drug Challenge
t2 to t3: 64min-83min
|
-9.88 percent change
Interval -23.9 to 1.5
|
17.08 percent change
Interval 4.36 to 37.09
|
21.02 percent change
Interval -23.89 to 43.86
|
|
Right Basal-Ganglia: Percent Change in GABA Levels After an Acute Drug Challenge
t3 to t4: 83min-102min
|
11.46 percent change
Interval -18.7 to 178.53
|
-0.82 percent change
Interval -9.81 to 37.07
|
-5.96 percent change
Interval -20.03 to 1.13
|
|
Right Basal-Ganglia: Percent Change in GABA Levels After an Acute Drug Challenge
t2 to t4: 64min-102min
|
10.15 percent change
Interval -7.73 to 64.39
|
35.96 percent change
Interval 5.21 to 47.5
|
14.20 percent change
Interval -3.22 to 37.44
|
PRIMARY outcome
Timeframe: from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)Population: One participant is missing GABA level at t4 while on Dextroamphetamine. Another participant is missing GABA levels both at t2 and t4 while on Dextroamphetamine. Another participant is missing GABA levels at both t2 and t4 while on Alprazolam.
The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge. GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100\*(later timepoint - earlier timepoint) / earlier timepoint
Outcome measures
| Measure |
Placebo
n=7 Participants
Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Placebo: single-dose, 1-day
|
Alprazolam
n=7 Participants
Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Alprazolam: Alprazolam, gel-capsule, 1mg, single-dose, 1-day
|
Dextroamphetamine
n=7 Participants
Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning
Dextroamphetamine: Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day
|
|---|---|---|---|
|
Right Temporal: Percent Change in GABA Levels After an Acute Drug Challenge
t1 to t2: 45min-64min
|
14.93 percent change
Interval -18.14 to 48.46
|
-1.45 percent change
Interval -19.95 to 4.29
|
2.09 percent change
Interval -44.68 to 40.24
|
|
Right Temporal: Percent Change in GABA Levels After an Acute Drug Challenge
t1 to t3: 45min-83min
|
21.26 percent change
Interval -29.56 to 62.94
|
24.29 percent change
Interval -57.06 to 49.03
|
-23.17 percent change
Interval -92.17 to 39.24
|
|
Right Temporal: Percent Change in GABA Levels After an Acute Drug Challenge
t1 to t4: 45min-102min
|
48.95 percent change
Interval 5.69 to 91.43
|
31.06 percent change
Interval -10.94 to 62.58
|
30.23 percent change
Interval -48.74 to 88.02
|
|
Right Temporal: Percent Change in GABA Levels After an Acute Drug Challenge
t2 to t3: 64min-83min
|
-13.91 percent change
Interval -39.87 to 21.8
|
-4.86 percent change
Interval -16.41 to 22.82
|
18.52 percent change
Interval -9.25 to 42.07
|
|
Right Temporal: Percent Change in GABA Levels After an Acute Drug Challenge
t3 to t4: 83min-102min
|
10.85 percent change
Interval 2.85 to 50.03
|
23.34 percent change
Interval 9.1 to 44.14
|
70.88 percent change
Interval 9.16 to 81.35
|
|
Right Temporal: Percent Change in GABA Levels After an Acute Drug Challenge
t2 to t4: 64min-102min
|
26.78 percent change
Interval -31.32 to 66.56
|
19.53 percent change
Interval 2.75 to 52.0
|
31.58 percent change
Interval -7.14 to 122.1
|
Adverse Events
Alprazolam
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Dextroamphetamine
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Placebo
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place